総合バリュエーションレンジ · 保守的 €180–€190 / 妥当 €235–€315 / 楽観的 €365–€400。€245.8 時点で 妥当な本源的価値レンジ内。
レポート公開時 €258.5（2026年6月29日）
UCB completed its acquisition of Candid Therapeutics for up to $2.2 billion, adding cizutamig to its immunology pipeline.
Possible impact:May affect expectations for UCB's immunology pipeline depth, capital allocation and long-term growth.
UCB and Biogen presented dapirolizumab pegol lupus data showing potential steroid reduction and flare control benefits.
Possible impact:May affect expectations for lupus commercialization probability and the partnered Biogen asset.
UCB completed the Neurona Therapeutics acquisition for up to $1.15 billion, adding rezanecel to its epilepsy portfolio.
Possible impact:May affect views on epilepsy innovation, development risk and acquisition integration costs.
UCB and Biogen reported Lancet publication of positive Phase 3 dapirolizumab pegol data in systemic lupus erythematosus.
Possible impact:May affect expectations for the lupus candidate's regulatory path and immunology pipeline value.
UCB reported Week 16 BE BOLD data showing BIMZELX superiority over SKYRIZI on ACR50 in psoriatic arthritis.
Possible impact:May affect BIMZELX competitive positioning, indication uptake and growth-driver expectations.
Automatically summarized from public sources; for context only, not investment advice.
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
近日公開このセクションは現在準備中です。近日公開予定です。
近日公開このセクションは現在準備中です。近日公開予定です。
この銘柄のレポートはお使いの言語でまだありません。
